Yervoy

(Ipilimumab)

ApprovedMonoclonal antibody

Ipilimumab is used to treat certain types of cancer, including melanoma and other cancers, by helping the immune system recognize and attack cancer cells.[2] Yervoy is currently approved and in use across 116 indications[4].[1]

Yervoy is one of 1347 biologic programs targeting Breast Cancer. It is currently in Approved.

116

Indications

709

Total Trials

Active Trials

1,346

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Breast CancerRecruiting

Cervical CancerCompleted

Urothelial CarcinomaCompleted

Prostate CancerUnknown status

Renal Cell CarcinomaCompleted

Pancreatic CancerCompleted

Soft Tissue SarcomaCompleted

Advanced Solid TumorsRecruiting

Metastatic NSCLCTerminated

ImmunotherapyUnknown status

Breast CancerPhase 2

Recruiting

Cervical CancerPhase 2

Completed

Urothelial CarcinomaPhase 2

Completed

Prostate CancerPhase 3

Unknown status

Renal Cell CarcinomaPhase 3

Completed

Pancreatic CancerPhase 2

Completed

Soft Tissue SarcomaPhase 2

Completed

Advanced Solid TumorsPhase 2

Recruiting

Metastatic NSCLCPhase 2

Terminated

ImmunotherapyPhase 2

Unknown status

Showing 10 of 116 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Approved

13 2

Adenocard

Astellas

Preclinical

2 3

Zolymbus

AbbVie

Preclinical

1 4

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Duragesic-100

CCephalon

Preclinical

2 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 8

Acupan

YYonsei University

Preclinical

1 9

Rilvegostomig

AstraZeneca

Preclinical

1 10

Paracetamol

GSK

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Pancreatic Cancer

NCT04361162

Phase 1/2Active, not recruiting

Glioblastoma

NCT03233152

Phase 1/2Active, not recruiting

Advanced NSCLC

NCT04043195

N/ARecruiting

Pancreatic Cancer

NCT06353646

Phase 1/2Active, not recruiting

Advanced Solid Cancers

NCT04317105

Q1 2027

Phase 2Active, not recruiting

Immunotherapy

NCT04969887

Clinical

Trials by Indication[1]

Melanoma38 trials

Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma

Terminated·UUniversity of Utah·Phase 1·NCT02200562·6 enrolled

Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01323517·26 enrolled

Radiation and Combination Immunotherapy for Melanoma

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03850691·4 enrolled

Show 35 more trials

Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

Completed· Novartis logo

Novartis··NCT05714371·618 enrolled

A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1

Unknown status·IItalian Network for Tumor Biotherapy Foundation·Phase 2·NCT04250246·184 enrolled

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma

Completed·TThe Netherlands Cancer Institute·Phase 1/2·NCT04133948·44 enrolled

A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02905266·106 enrolled

Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma

Terminated·JJason J. Luke, MD·Phase 1/2·NCT04655157·2 enrolled

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

Completed·NNYU Langone Health·Phase 2·NCT02970981·18 enrolled

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT02032810·17 enrolled

A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases

Completed·UUniversitair Ziekenhuis Brussel·Phase 1/2·NCT02941744·56 enrolled

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01866319·834 enrolled

Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma

Completed·—·Phase 1·NCT02115243·4 enrolled

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

Completed·HH. Lee Moffitt Cancer Center and Research Institute·N/A·NCT01701674·13 enrolled

Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I)

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT05169957·2 enrolled

Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00289640·210 enrolled

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Completed·UUltimovacs ASA·Phase 2·NCT04382664·156 enrolled

Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases

Recruiting·MMelanoma and Skin Cancer Trials Limited·Phase 1/2·NCT06163820·46 enrolled

Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00357461

Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

Recruiting·FFox Chase Cancer Center·Phase 1·NCT05498792·12 enrolled

Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma

Completed·—·Phase 2·NCT01363206·29 enrolled

Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

Recruiting·SStanford University·Phase 2·NCT06712927·60 enrolled

A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03978611·11 enrolled

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02388906·906 enrolled

A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT06594991·88 enrolled

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01709162·31 enrolled

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

Completed· Amgen logo

Amgen·Phase 1/2·NCT01740297·217 enrolled

A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma

Terminated·CCraig L Slingluff, Jr·Phase 1/2·NCT02385669·3 enrolled

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00032045

Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00636168·1,211 enrolled

Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery

Completed·—·Phase 2·NCT02158520·24 enrolled

Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma

Withdrawn·RRabih Said·Phase 1/2·NCT02452281

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

Active, not recruiting·—·Phase 1·NCT03929029·11 enrolled

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00084656·77 enrolled

Melanoma Metastasized to the Brain and Steroids

Recruiting·IInge Marie Svane·Phase 2·NCT03563729·80 enrolled

A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00289627·155 enrolled

RTA 408 Capsules in Patients With Melanoma - REVEAL

Completed· Biogen logo

Biogen·Phase 1/2·NCT02259231·41 enrolled

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Recruiting·NNYU Langone Health·Phase 2·NCT05428007·105 enrolled

Metastatic Melanoma13 trials

IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma

Completed·IInstitute of Oncology Ljubljana·N/A·NCT07436390·132 enrolled

A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1/2·NCT02857569·90 enrolled

Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients

Terminated·SSheba Medical Center·Phase 2·NCT01988077·2 enrolled

Show 10 more trials

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02714218·387 enrolled

A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma

Completed·IItalian Network for Tumor Biotherapy·Phase 2·NCT01654692·86 enrolled

Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma

Terminated·NNYU Langone Health·Phase 2·NCT01689974·10 enrolled

CD8+ Antigen-Specific T Cells, Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Melanoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02027935·16 enrolled

Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression

Terminated·EElizabeth Davis·Phase 2·NCT03724968·2 enrolled

Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

Recruiting·SSheba Medical Center·Phase 2·NCT03166397·30 enrolled

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00871481·10 enrolled

Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01827111·21 enrolled

Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma

Completed·TThe Netherlands Cancer Institute·Phase 3·NCT02278887·168 enrolled

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

Active, not recruiting·BBioInvent International AB·Phase 1/2·NCT06784648·35 enrolled

Non-Small Cell Lung Cancer11 trials

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02477826·2,747 enrolled

An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03001882·230 enrolled

Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01471197·9 enrolled

Show 8 more trials

Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03302234·568 enrolled

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04026412·925 enrolled

Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT03663166·19 enrolled

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2

Terminated· GSK logo

GSK·Phase 2·NCT06790303·8 enrolled

A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02998528·505 enrolled

Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)

Completed·NNYU Langone Health·Phase 1/2·NCT02221739·39 enrolled

Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01454102·472 enrolled

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

Completed·UUniversity of Utah·Phase 1·NCT01998126·14 enrolled

Pancreatic Cancer8 trials

Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer

Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT04361162·30 enrolled

Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.

Terminated·HHerlev Hospital·Phase 2·NCT05116917·19 enrolled

Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03190265·61 enrolled

Show 5 more trials

MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00112580·27 enrolled

FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01896869·83 enrolled

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT06941857·20 enrolled

Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer

Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT03104439·84 enrolled

XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer

Recruiting·WWu Wenming·N/A·NCT06353646·28 enrolled

Prostate Cancer6 trials

A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer

Unknown status·SSpanish Oncology Genito-Urinary Group·Phase 2/3·NCT03879122·135 enrolled

Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer

Terminated·UUniversity Hospital, Essen·Phase 1/2·NCT06388369·1 enrolled

Neoadjuvant Ipilimumab in Prostate Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01194271·19 enrolled

Show 3 more trials

Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT02601014·32 enrolled

Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02279862·82 enrolled

Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer

Completed·PProstate Oncology Specialists, Inc.·Phase 1·NCT01832870·9 enrolled

86 more indications

Glioblastoma6 trials

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04817254·47 enrolled

Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma

Terminated·BBaptist Health South Florida·Phase 2·NCT03430791·5 enrolled

A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed Glioblastoma

Terminated·UUniversity College, London·Phase 2·NCT05074992·1 enrolled

Show 3 more trials

Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma

Terminated·WWashington University School of Medicine·Phase 1·NCT03422094·3 enrolled

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Completed·NNational Cancer Institute (NCI)·Phase 2/3·NCT04396860·159 enrolled

A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.

Active, not recruiting·UUniversitair Ziekenhuis Brussel·Phase 1/2·NCT03233152·110 enrolled

Hepatocellular Carcinoma5 trials

Neoadjuvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.

Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT06492408·90 enrolled

Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment

Not yet recruiting·FFudan University··NCT07147101·150 enrolled

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT04248569·56 enrolled

Show 2 more trials

Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1·NCT04823403·27 enrolled

Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy

Completed·FFederation Francophone de Cancerologie Digestive·Phase 2/3·NCT05665348·229 enrolled

Nivolumab4 trials

CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT04060407

Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC

Recruiting·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT05310643·30 enrolled

IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM

Recruiting·—·Phase 1·NCT04003649·60 enrolled

Show 1 more trial

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT02658890·627 enrolled

Small Cell Lung Cancer4 trials

Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT03043599·21 enrolled

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT03377023·66 enrolled

Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01285609·1,289 enrolled

Show 1 more trial

Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT03406715·14 enrolled

Lung Cancer3 trials

Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT

Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT06483347·90 enrolled

Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.

Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT06492421·90 enrolled

Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01165216·15 enrolled

Immunotherapy3 trials

PHP and Immunotherapy in Metastasized UM

Active, not recruiting·LLeiden University Medical Center·Phase 1/2·NCT04283890·83 enrolled

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03459222·229 enrolled

Combination Immunotherapy in Rare Cancers Under InvesTigation

Active, not recruiting·OOlivia Newton-John Cancer Research Institute·Phase 2·NCT04969887·240 enrolled

Renal Cell Carcinoma3 trials

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02231749·1,390 enrolled

NeoVax Plus Ipilimumab in Renal Cell Carcinoma

Active, not recruiting·—·Phase 1·NCT02950766·19 enrolled

Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary

Terminated·—·Phase 1·NCT04429321·1 enrolled

Pleural Mesothelioma2 trials

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Completed·PPrECOG, LLC.·Phase 3·NCT04334759·214 enrolled

A Study to Evaluate Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin for Unresectable Pleural Mesothelioma in Chinese Participants

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT05136677·102 enrolled

Metastasis2 trials

A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis

Unknown status·IItalian Network for Tumor Biotherapy Foundation·Phase 3·NCT02460068·168 enrolled

Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis

Completed·UUniversity Hospital, Strasbourg, France·Phase 1/2·NCT03949153·19 enrolled

Advanced Solid Tumors2 trials

Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors

Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 1/2·NCT05187338·100 enrolled

First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03110107·376 enrolled

Chemoradiotherapy2 trials

Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC

Active, not recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT05200988·50 enrolled

Study to Nivolumab Following Preoperative Chemoradiotherapy

Unknown status·TTakayuki Yoshino·Phase 1/2·NCT02948348·90 enrolled

Solid Tumors2 trials

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

Active, not recruiting·VVyriad, Inc.·Phase 1/2·NCT03647163·33 enrolled

Ipilimumab and Local Radiation for Selected Solid Tumors

Terminated·SStanford University·Phase 1·NCT01769222·3 enrolled

Metastatic Colorectal Cancer2 trials

iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab

Active, not recruiting·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT03350126·57 enrolled

Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation

Completed· Pfizer logo

Pfizer·Phase 2·NCT03271047·75 enrolled

Lymphoma2 trials

MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00089076·18 enrolled

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

Terminated·CCytomX Therapeutics·Phase 1/2·NCT03013491·196 enrolled

Advanced NSCLC2 trials

Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC

Active, not recruiting·HHatim Husain·Phase 1/2·NCT04043195·30 enrolled

Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

Recruiting·HHackensack Meridian Health·Phase 2·NCT05715229·108 enrolled

Breast Cancer2 trials

Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Breast Cancer

Completed·OOslo University Hospital·Phase 2·NCT03409198·82 enrolled

Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease

Unknown status·CCentre Leon Berard·Phase 2·NCT03818685·95 enrolled

Advanced Solid Cancers2 trials

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT04317105·54 enrolled

An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03956680·54 enrolled

Squamous Cell Carcinoma2 trials

Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02741570·947 enrolled

Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02823574·425 enrolled

Patients With Advanced Solid Tumors2 trials

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03251924·80 enrolled

A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT01714739·337 enrolled

Uveal Melanoma2 trials

Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases

Unknown status·—·Phase 1/2·NCT02913417·26 enrolled

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Active, not recruiting·IIDEAYA Biosciences·Phase 2/3·NCT05987332·420 enrolled

Refractory Solid Tumors2 trials

Vopratelimab (JTX-2011) Alone and in Combination With Anti-Programmed Cell Death Protein 1 (PD-1) or Anti-Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) in Subjects With Advanced and/or Refractory Solid Tumors

Terminated·JJounce Therapeutics, Inc.·Phase 1/2·NCT04319224·4 enrolled

JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors

Completed·JJounce Therapeutics, Inc.·Phase 1/2·NCT02904226·242 enrolled

Soft Tissue Sarcoma2 trials

Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma

Active, not recruiting·NNational Cancer Institute LAO·Phase 2·NCT05836571·66 enrolled

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03449108·30 enrolled

Ovarian Cancer2 trials

TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

Completed·IInge Marie Svane·Phase 1/2·NCT03287674·7 enrolled

Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01611558·40 enrolled

Metastatic NSCLC1 trial

Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)

Recruiting·GGazi University··NCT07394062·400 enrolled

HCC1 trial

Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT

Recruiting·SSecond Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT06482801·90 enrolled

Trial1 trial

The Drug Rediscovery Protocol (DRUP Trial)

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT02925234·1,550 enrolled

Budesonide1 trial

A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00135408·115 enrolled

Brain Tumors1 trial

Improved Therapy Response Assessment in Metastatic Brain Tumors

Unknown status·OOslo University Hospital··NCT03458455·200 enrolled

Immune System1 trial

Study of Ipilimumab in the Immune System

Completed·UUniversity Health Network, Toronto·N/A·NCT01715077·4 enrolled

Patients With Solid Tumors1 trial

Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors

Withdrawn·PPartner Therapeutics, Inc.·Phase 2·NCT05284214

Colorectal Cancer1 trial

Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer

Not yet recruiting·FFudan University·Phase 2·NCT07403877·114 enrolled

Cytoreductive Nephrectomy1 trial

Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC

Not yet recruiting·SSeoul National University Hospital·N/A·NCT07233668·172 enrolled

Hepatocellular Cancer1 trial

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

Not yet recruiting·UUniversity of Hawaii·Phase 1·NCT07075120·15 enrolled

Randomized1 trial

Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC

Completed·GGoethe University·Phase 2·NCT03075423·316 enrolled

Cervical Cancer1 trial

Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

Recruiting·HHospital Israelita Albert Einstein·Phase 2·NCT05492123·112 enrolled

Gastric Adenocarcinoma1 trial

Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.

Active, not recruiting·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT04006262·32 enrolled

Dendritic Cell1 trial

Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors

Unknown status·UUniversitair Ziekenhuis Brussel·Phase 2·NCT04571632·36 enrolled

Stem Cell Transplant1 trial

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00060372·21 enrolled

Refractory Cancer1 trial

Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT03388632·31 enrolled

Renal Cell Cancer1 trial

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

Suspended·MMichael B. Atkins, MD·Phase 2·NCT05928806·120 enrolled

Metastatic1 trial

Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation

Withdrawn·UUniversity of Utah·Phase 1·NCT04315155

Tumors1 trial

Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors

Terminated·TTriSalus Life Sciences, Inc.·Phase 1/2·NCT05220722·23 enrolled

Advanced or Recurrent Solid Tumors1 trial

A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03195478·37 enrolled

Advanced1 trial

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01750580·22 enrolled

Safety and Efficacy1 trial

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Completed·IIncyte Biosciences International Sàrl·Phase 1/2·NCT03241173·52 enrolled

Endometrial Carcinoma1 trial

A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma

Unknown status·—·Phase 2·NCT02982486·60 enrolled

Advanced Solid Malignancies1 trial

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT02668770·28 enrolled

Urothelial Cancer1 trial

Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer

Completed·JJounce Therapeutics, Inc.·Phase 2·NCT03989362·61 enrolled

Central Nervous System1 trial

A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03130959·166 enrolled

Neuroendocrine Tumors1 trial

Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03420521·9 enrolled

Solid Cancers1 trial

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT02737475·166 enrolled

Personalized Cancer Vaccine1 trial

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

Completed·GGritstone bio, Inc.·Phase 1/2·NCT03953235·39 enrolled

Phase II1 trial

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00261365·80 enrolled

Cutaneous Melanoma1 trial

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

Terminated·PProvidence Health & Services·Phase 2·NCT05200143·4 enrolled

Adverse Events1 trial

Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT03165409·1,828 enrolled

Toxicity1 trial

Microbiome Immunotherapy Toxicity and Response Evaluation

Unknown status·CCCTU- Cancer Theme··NCT04107168·1,800 enrolled

Adult1 trial

A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT04868760·148 enrolled

Monotherapy1 trial

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Recruiting·77 Hills Pharma, LLC·Phase 1/2·NCT06362369·126 enrolled

Head and Neck Carcinoma1 trial

ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma

Completed·TThe Netherlands Cancer Institute·Phase 1/2·NCT03003637·33 enrolled

Cholangiocarcinoma1 trial

Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma

Terminated·SServier Bio-Innovation LLC·Phase 1/2·NCT05921760·7 enrolled

Advanced Cancers1 trial

Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers

Terminated·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1·NCT04270864·25 enrolled

Cell Therapy1 trial

Adoptive Cell Therapy Across Cancer Diagnoses

Completed·IInge Marie Svane·Phase 1/2·NCT03296137·25 enrolled

Salivary Gland Cancer1 trial

Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers

Completed·UUniversity of Washington·Phase 1/2·NCT03749460·20 enrolled

PDL-11 trial

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

Recruiting·UUniversity of Alabama at Birmingham·Phase 2·NCT06364917·24 enrolled

Resistant Cancer1 trial

Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01445379·33 enrolled

Mucosal Melanoma1 trial

Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma

Active, not recruiting·—·Phase 2·NCT03241186·36 enrolled

Neuroendocrine Carcinoma1 trial

SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

Recruiting·PPeter Hosein, MD·Phase 1·NCT06889493·36 enrolled

Autologous Stem Cell Transplantation1 trial

Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence

Terminated·HHackensack Meridian Health·Phase 1/2·NCT02681302·46 enrolled

Metastatic Prostate Cancer1 trial

A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer

Active, not recruiting·—·Phase 2·NCT04709276·41 enrolled

Chemotherapy1 trial

Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

Completed·MMassachusetts General Hospital·Phase 2·NCT03256136·9 enrolled

Colorectal1 trial

Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors

Terminated·—·Phase 2·NCT03693846·11 enrolled

Kidney Cancer1 trial

A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT03873402·437 enrolled

Lymphoid Malignancies1 trial

Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01919619·41 enrolled

Clinical Trial1 trial

CARE1 Pragmatic Clinical Trial

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT06364631·1,250 enrolled

Stomach Cancer1 trial

Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02872116·2,031 enrolled

Relapsed/Refractory1 trial

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Withdrawn·NNational Cancer Institute (NCI)·Phase 1·NCT04500548

Intratumoral Injection1 trial

A Phase I/II Study of Intratumoral Injection of SD-101

Completed·RRobert Lowsky·Phase 1/2·NCT02254772·9 enrolled

Immune Checkpoint Inhibition1 trial

Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition

Completed·UUniversity of Erlangen-Nürnberg Medical School··NCT03453892·150 enrolled

Metastatic Solid Tumors1 trial

Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery

Withdrawn·NNational Cancer Institute (NCI)·Phase 1/2·NCT03326258

Gastric Cancer1 trial

Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.

Unknown status·NNational University Hospital, Singapore·Phase 1·NCT03784040·40 enrolled

Malignant Pleural Mesothelioma1 trial

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03918252·30 enrolled

Brain Cancer1 trial

A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.

Recruiting·UUniversity College, London·Phase 1·NCT07134842·16 enrolled

mCRPC1 trial

Checkpoint Inhibitors and SBRT for MCRPC

Completed·HHerlev and Gentofte Hospital·Phase 2·NCT05655715·90 enrolled

Pancreatic Adenocarcinoma1 trial

Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Completed·CCancer Insight, LLC·Phase 1·NCT04787991·45 enrolled

Sarcoma1 trial

Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01400451·18 enrolled

Unspecified2 trials

Adoptive Therapy Using Antigen-Specific CD4 T-Cells

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT02210104

Ipilimumab 12-month Intensive Pharmacovigilance Protocol

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02050594·6 enrolled

Regulatory

FDA Approval Timeline[5]

Mar 25, 2011

YERVOY

NDA BLA125377

Mar 25, 2011

YERVOY

BLA BLA125377

Jul 28, 2011

YERVOY

NDA BLA125377

Feb 16, 2012

YERVOY

NDA BLA125377

Oct 26, 2012

YERVOY

NDA BLA125377

May 22, 2013

YERVOY

NDA BLA125377

Dec 5, 2013

YERVOY

NDA BLA125377

Mar 16, 2015

YERVOY

NDA BLA125377

Mar 19, 2015

YERVOY

NDA BLA125377

Aug 17, 2015

YERVOY

NDA BLA125377

Oct 28, 2015

YERVOY

NDA BLA125377

Mar 3, 2017

YERVOY

NDA BLA125377

Jul 21, 2017

YERVOY

NDA BLA125377

Oct 20, 2017

YERVOY

NDA BLA125377

Dec 13, 2017

YERVOY

NDA BLA125377

Feb 8, 2018

YERVOY

NDA BLA125377

Apr 16, 2018

YERVOY

NDA BLA125377

Jul 10, 2018

YERVOY

NDA BLA125377

May 8, 2019

YERVOY

NDA BLA125377

Sep 20, 2019

YERVOY

NDA BLA125377

Mar 10, 2020

YERVOY

NDA BLA125377

May 15, 2020

YERVOY

NDA BLA125377

May 26, 2020

YERVOY

NDA BLA125377

Jun 29, 2020

YERVOY

NDA BLA125377

Aug 13, 2020

YERVOY

NDA BLA125377

Sep 18, 2020

YERVOY

NDA BLA125377

Oct 2, 2020

YERVOY

NDA BLA125377

Nov 13, 2020

YERVOY

NDA BLA125377

May 25, 2021

YERVOY

NDA BLA125377

Feb 25, 2022

YERVOY

NDA BLA125377

Feb 25, 2022

YERVOY

NDA BLA125377

May 11, 2022

YERVOY

NDA BLA125377

May 27, 2022

YERVOY

NDA BLA125377

Nov 23, 2022

YERVOY

NDA BLA125377

Feb 15, 2023

YERVOY

NDA BLA125377

Jan 28, 2025

YERVOY

NDA BLA125377

Apr 8, 2025

YERVOY

NDA BLA125377

Apr 11, 2025

YERVOY

NDA BLA125377

May 23, 2025

YERVOY

NDA BLA125377

Jun 12, 2026

YERVOY

NDA BLA125377

Aug 31, 2026

YERVOY

NDA BLA125377

Sources

References

[1]
ClinicalTrials.gov — 709 trial records for Ipilimumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Yervoy drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Ipilimumab compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Ipilimumab. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA BLA125377). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Cytotoxic T-Lymphocyte Protein 4 Inhibitor[3]
Modality: Monoclonal antibody[3]
Highest Phase: Approved[1]
Company: Bristol-Myers Squibb